Turning groundbreaking research from the Institut Pasteur with the support of Argobio’s start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections. The platform leverages state-of-the-art generative artificial intelligence (AI) to design selective inhibitors of the Sec61/translocon molecular complex for blocking and degrading disease-causing proteins. Enodia Therapeutics is the winner of Pfizer sponsor BioLabs Paris Hotel Dieu coveted 2025 Golden Ticket competition. Paris, France - 26/02/2025 - Argobio and the Institut Pasteur proudly announce the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections. “With the convergence of an unprecedented diverse set of small molecules inhibitors of the Sec61/translocon molecular complex and advancements in generative artificial intelligence (AI), our vision is to develop novel small molecules drugs with good pharmaceuticals properties that could overcome the most critical limitations of today’s medicines,” said Yves Ribeill, CEO of Enodia Therapeutics. Enodia Therapeutics stems from pioneering research at the Institut Pasteur, with the discovery of the mechanism of action of Mycolactone, a natural Sec61 inhibitor responsible for Buruli Ulcers. "Our infectious diseases research revealed a new way to target disease-causing proteins. This breakthrough highlights how fundamental research can help uncover entirely new therapeutic opportunities," said Pr. Caroline Demangel, cofounder of Enodia Therapeutics and Head of the Immunobiology and Therapy Unit at the Institut Pasteur. Rooted in groundbreaking research at the Institut Pasteur and supported by Argobio, Enodia Therapeutics received Pfizer x BioLabs’ prestigious Golden Ticket Award. “This recognition supports our newest small molecule Targeted Protein Degrader (TPD) developed by the combined teams of Argobio and the Institut Pasteur. We are grateful for Pfizer’s support and proud to be part of the vibrant BioLabs life sciences ecosystem in Paris Hotel Dieu, where collaboration and innovation are driving significant advancements in healthcare” Yves Ribeill remarked. "Pfizer is committed to supporting innovative biotech startups that have the potential to redefine patient care. We are excited to see how Enodia Therapeutics will harness its technology for novel treatment approaches," said Dr. Luca Mollo, Vice-President and Medical Director at Pfizer in France. Enodia Therapeutics was incubated by Argobio, a premier French biotech studio company dedicated to fostering innovative science and accelerating its transition into a fully-fledged biotech company. The scientific project behind Enodia Therapeutics was supported by the Institut Pasteur’s Innovation Accelerator. The aim of this program is to accelerate the market launch of innovative products resulting from laboratory discoveries. With the creation of its first spin-off company in 1997, the Institut Pasteur has been a pioneer in the creation of spin-off companies based on its research. To date the Institut Pasteur has been involved in the development of 38 spin-off companies.

Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Enodia Financing co-led by Elaia, Pfizer Ventures and Bpifrance Enodia is the third Argobio-founded company to achieve a seed financing in 2025 Paris, France – 08 January 2026. Argobio Studio, the launch platform for Europe’s best innovative science, today announced the successful seed financing of Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of protein synthesis. Enodia has secured €20.7 million (US$25 million) in Seed financing, co-led by Elaia, Pfizer Ventures and Bpifrance, as part of the InnoBio investment strategy,with participation from Wallonie Entreprendre, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital in addition to Argobio. Enodia Therapeutics was created by Argobio Studio after it identified the pioneering foundational research by a leading researcher from the Pasteur Institute. Enodia’s proprietary discovery platform uses machine learning to selectively modulate the SEC61 translocon, where secreted and transmembrane proteins are directed into the secretory pathway at the point of synthesis. This enables intervention upstream of disease, without compromising vital physiological functions, and before damage occurs. The platform leverages a large chemical space spanning several families of well-characterized inhibitors, together with a tailored library of signal-peptide cell lines. The company integrates machine- learning-driven selectivity, proteomics based secretome analysis and structural validation to guide rational drug design. This innovative strategy allows Enodia to unlock previously undruggable secreted and membrane protein targets to treat high-unmet-need conditions. “Enodia is the third of eight companies created by Argobio to achieve seed financing, underscoring the strength and consistency of our studio model,” said Daniel Sobral, Chief Financial Officer and Head of Corporate Development at Argobio. “Our operational venture-building approach is designed to rapidly translate Europe’s leading scientific innovation into globally competitive biotech companies. Enodia is a strong example of this model, based on exceptional foundational research from Institut Pasteur and built by Argobio. We are proud to have brought together a high-quality syndicate of leading international investors to support the company through its next stage of development.” “We are grateful for the strong support and confidence of our investor syndicate, and in particular for Argobio’s long-term commitment and company-building approach,” said Yves Ribeill, Chief Executive Officer of Enodia Therapeutics, who also served as Entrepreneur in Residence at Argobio during Enodia’s inception. “Working closely with the Argobio team from the outset enabled us to shape Enodia’s strategy and more rapidly assemble our industrial capabilities while also advancing our highly differentiated small-molecule approach to selectively modulating the SEC61 translocon. With this financing, we are well positioned to progress our lead program to preclinical candidate selection over the coming year, representing an important value inflection point for Enodia.” Enodia is the third Argobio company to successfully complete its seed financing in the last eight months. Elkedonia, announced an €11.25 million seed financing in June 2025 to advance discovery of its first-in-class antidepressant candidates, non-hallucinogenic neuroplasticity enhancers, for treatment-resistant depression. Laigo Bio announced an €11.5 million seed financing in December 2025 to advance its proprietary SureTAC™ precision membrane protein degradation platform. Enodia Therapeutics (www.enodiatx.com) is a biotechnology company that develops best-in-class small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis before they have a damaging effect. The company’s platform combines a proteomics informed understanding of the secretome with machine-learning–enabled selectivity to support rational drug design. Rooted in pioneering academic research from the Institut Pasteur and built by Argobio Studio, Enodia is advancing a pipeline initially focused on inflammatory and autoimmune diseases, with additional opportunities across oncology and viral infections enabled by the same underlying biological mechanism. Argobio Studio (www.argobiostudio.com) is thelaunch platformfor Europe’s best science. We turn cutting-edge science into globally competitive European companies pioneering breakthrough therapeutics for patients around the world. As operational venture builders, we reduce execution risk by co-founding, investing, and embedding our experienced, collaborative team, accelerating development with industrial rigor and speed toward value-creating milestones.